185 filings
Page 8 of 10
6-K
ejoc qet9y
4 May 18
Current report (foreign)
4:58pm
EFFECT
t0zij al5cmp3dd
4 May 18
Notice of effectiveness
12:15am
F-1
9xewlfpbd
2 May 18
Registration statement (foreign)
7:10am
DRSLTR
acncx1w
2 May 18
Correspondence regarding draft registration statement
12:00am
CORRESP
97kq9f
2 May 18
Correspondence with SEC
12:00am
CORRESP
ny04h9d5m0c
2 May 18
Correspondence with SEC
12:00am
DRSLTR
veqkzuy7 mw77c
1 May 18
Correspondence regarding draft registration statement
12:00am
UPLOAD
crdlhh4mbby
1 May 18
Letter from SEC
12:00am
DRS
gl3j cozhzm
23 Apr 18
Draft registration statement
12:00am
20-F
agdclqlt4qubyhf6ppd
29 Mar 18
Annual report (foreign)
12:00am
6-K
xhx p6dfj3
29 Mar 18
InflaRx Full Year 2017 Financial & Operating Results
12:00am
6-K
6p1yz3ttj7kciiukj66p
8 Mar 18
InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa
12:00am
6-K
9cpcp8
6 Feb 18
InflaRx announces appointment of Tony Gibney
12:00am
6-K
45xka8zt66 412ev
22 Jan 18
Current report (foreign)
12:00am
6-K
od1y14d8k 9l58d
9 Jan 18
InflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa
12:00am
6-K
40iq51
21 Dec 17
Current report (foreign)
12:00am
S-8
tkll9 i9svkt
17 Nov 17
Registration of securities for employees
12:00am
POS EX
8wve6pvlr7 jb
9 Nov 17
Additional exhibits for listing
12:00am
CT ORDER
r9vvnj w6
8 Nov 17
Confidential treatment order
12:00am
424B4
qdfvm
8 Nov 17
Prospectus supplement with pricing info
12:00am